Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 14/20 | 0.72 |
| ▸ | ESR1 | P03372 | 13/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981042 | 0.86 | ESR2 (0.70) | ESR2ESR1NPC1TP53MAPK1 | |
| SCHEMBL5981008 | 0.85 | ESR1 (0.72) | ESR2ESR1 | |
| SCHEMBL3925187 | 0.84 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL3934274 | 0.82 | ESR1 (1.00) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL5980138 | 0.77 | ESR1 (0.43) | ESR2ESR1NPC1TP53MAPK1 | |
| SCHEMBL7944523 | 0.77 | NPC1 (0.52) | ESR2NPC1TP53MAPK1CASP3 | |
| SCHEMBL19956077 | 0.75 | ESR2 (0.55) | ESR2ESR1NPC1TP53MAPK1 | |
| SCHEMBL5981371 | 0.73 | ESR1 (0.76) | ESR2ESR1 | |
| SCHEMBL5981200 | 0.72 | ESR2 (0.73) | ESR2ESR1NPC1TP53MAPK1 | |
| SCHEMBL5981427 | 0.71 | ESR1 (0.64) | ESR2ESR1NPC1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | MEWSHAW RICHARD E (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR2 1/4885ESR1 2/4885NPC1 994/4885 |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR2 1/4885ESR1 2/4885NPC1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.